FDA skeptical of experimental ALS treatment pushed by patient advocates

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.

NurOwn is the clearest test yet of how far the agency may be willing to bend to approve a new medicine for a rare and deadly condition with few treatment options.

The meeting was scheduled after ALS advocates delivered a 30,000-signature petition seeking a public vetting of the treatment. "The amazing testimonials we have seen online do not align with the data that Brainstorm has shared," the group said in a statement. NurOwn is made from stem cells collected from patients' bone marrow. The cells are processed in a lab with biological proteins designed to promote nerve growth, and then injected into the spinal column.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

KPRC2 /  🏆 80. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
Les mer »

FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
Les mer »

FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease
Les mer »

FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
Les mer »

Some cold medicines might not work according to FDAThe drug is known as phenylephrine. It’s found in medicine you probably have at home, like Dayquil and Mucinex.
Les mer »

Coherus BioSciences’ new injector treatment for cancer patients rejected by FDACoherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a...
Les mer »